Tharimmune to Present at the Microcap Conference 2025
-
Medieval Europe and Africa collide in Sao Tome traditional theatre
-
Far-right AfD eyes huge win in east German state vote
-
Iran attacks US targets despite Trump threats
-
Brazil-Japan to play World Cup rematch at Singapore tournament
-
Alcaraz believes 'impossible' schedule raising injury threat
-
Defence chiefs back boosting US military presence in Australia
-
Alcaraz rallies to reach US Open third round, Sabalenka storms through
-
Nepal seeks climate justice after Himalayan disaster
-
Alcaraz overpowers Faria to reach US Open third round
-
Stocks rise, yields ease as oil slips on Trump hint at short bombing campaign
-
Hamilton hopes to boost title bid with record Italian triumph
-
Brussels Diamond League finals Day 1 - five events to watch
-
Iran, US trade threats after fresh strikes
-
Thailand's 'Jurassic Park' shines light on dinosaur evolution
-
US not 'stealing Venezuelan oil,' energy secretary insists
-
'Role model' Stokes set to open for Adelaide Strikers
-
Farming experts tout 'conscious' food systems to fix agriculture woes
-
Palau urges 'unified' Pacific response to China missile test
-
George Lucas unveils art galaxy at his new LA museum
-
Grinding away: in remote Appalachia, old mills fuel US clean food dreams
-
Veteran Wallaby Slipper targets fifth World Cup after Brumbies deal
-
Sabalenka races into US Open third round
-
Sabalenka storms into US Open third round as Pegula, Medvedev advance
-
Costa Rica Makes History as First Latin American Country to Launch English Learning as a National Initiative with Open English
-
Chinese lucky loser stuns Jodar at US Open
-
Zverev looks to improve after first-round scare
-
US Open under the influence: content creators spark debate
-
Raiders to start Cousins over top NFL Draft pick Mendoza
-
NBA hammers Clippers over Leonard salary cap violations
-
Palantir chief says France's digital sovereignty push 'backfiring'
-
NBA strips five first-round draft picks from Clippers for Leonard salary cap violations
-
US energy firms dominate Venezuela deals worth billions
-
Kane brace helps Bayern win German Cup opener
-
Iran, US trade threats after escalation in fighting
-
Migrant plight, local anger divide Ceuta one month after influx
-
US jury deadlocks again in Lindsay Clancy's child murder trial
-
Outrage as Maltese tycoon acquitted of reporter's murder
-
Lake America? No way, Canadians say
-
Rare train of Pacific cyclones fueled by historic El Nino
-
Spain report flags Moroccan police failings in Ceuta migrant rush
-
Macron, King Charles hail UK-France ties after viewing Bayeux Tapestry
-
Tech bosses press G20 to build data centers, but split on risk
-
Fury hits out at 'coward' Joshua as 'Battle of Britain' talks go on
-
Dolly Parton to get new Hollywood star after vandalism
-
Maltese tycoon acquitted of masterminding reporter's murder
-
Trump 'happy' Prince Harry and Meghan have left US
-
George Clooney: a Hollywood icon and campaigner
-
Michelson shocks Nakashima in US Open clash of rising Americans
-
Europe, US closer than they look on tech rules, says EU tech chief
-
Another body recovered after ferry capsizes off northern Cyprus: official
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
